Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Capital Leases (2019 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Capital Leases for 5 consecutive years, with $864000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Capital Leases fell 62.98% year-over-year to $864000.0, compared with a TTM value of $864000.0 through Sep 2023, down 62.98%, and an annual FY2022 reading of $2.2 million, down 51.57% over the prior year.
  • Capital Leases was $864000.0 for Q3 2023 at Alaunos Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Capital Leases topped out at $4.5 million in Q4 2021 and bottomed at $647000.0 in Q3 2019.
  • Average Capital Leases over 5 years is $2.0 million, with a median of $1.7 million recorded in 2020.
  • The sharpest move saw Capital Leases soared 155.8% in 2020, then tumbled 62.98% in 2023.
  • Year by year, Capital Leases stood at $647000.0 in 2019, then surged by 517.47% to $4.0 million in 2020, then increased by 13.09% to $4.5 million in 2021, then tumbled by 51.57% to $2.2 million in 2022, then plummeted by 60.51% to $864000.0 in 2023.
  • Business Quant data shows Capital Leases for TCRT at $864000.0 in Q3 2023, $1.2 million in Q2 2023, and $2.0 million in Q1 2023.